Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00054236
First received: February 5, 2003
Last updated: September 11, 2012
Last verified: September 2012
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy followed by umbilical cord blood transplantation in treating patients who have hematologic cancer or severe aplastic anemia.


Condition Intervention Phase
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: umbilical cord blood transplantation
Drug: methylprednisolone
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Leukemia, Myeloid Chronic Myeloid Leukemia Myelodysplastic Syndromes Lymphoma, Small Cleaved-cell, Diffuse Acute Lymphoblastic Leukemia Multiple Myeloma Chronic Myeloproliferative Disorders Hodgkin Lymphoma Aplastic Anemia Acute Myelocytic Leukemia Acute Non Lymphoblastic Leukemia Myelodysplastic/myeloproliferative Disease Acute Myeloid Leukemia, Adult Follicular Lymphoma Hodgkin Lymphoma, Childhood B-cell Lymphomas Myelofibrosis Burkitt Lymphoma Lymphoma, Large-cell Lymphoma, Large-cell, Immunoblastic Lymphoblastic Lymphoma Small Non-cleaved Cell Lymphoma Anaplastic Large Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia, B-cell, Chronic Acute Lymphoblastic Leukemia, Childhood Chronic Neutrophilic Leukemia Hypereosinophilic Syndrome Acute Myeloid Leukemia, Childhood Mantle Cell Lymphoma Acute Erythroblastic Leukemia Acute Erythroid Leukemia Di Guglielmo's Syndrome Acute Megakaryoblastic Leukemia Polycythemia Vera Essential Thrombocythemia Anaplastic Plasmacytoma
U.S. FDA Resources

Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Event-free survival by disease assessment [ Time Frame: at 28 and 100 days and then at 6, 9, 12, 18, and 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) [ Time Frame: monthly for 6 months and then at 9, 12, 18, and 24 months ] [ Designated as safety issue: No ]

Enrollment: 55
Study Start Date: May 2002
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: non-myeloablative conditioning regimen Biological: anti-thymocyte globulin
anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
Biological: filgrastim
Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
Drug: cyclophosphamide
cyclophosphamide IV over 2 hours on days -3 to -2
Drug: fludarabine phosphate
fludarabine IV over 30 minutes on days -8 to -4
Procedure: umbilical cord blood transplantation
Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
Drug: methylprednisolone
Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.

Detailed Description:

OBJECTIVES:

  • Determine the incidence and severity of acute toxicity in patients with hematologic malignancies or severe aplastic anemia treated with a non-myeloablative conditioning regimen followed by umbilical cord blood transplantation.
  • Determine the incidence and severity of acute and chronic graft-versus-host-disease in patients treated with this regimen.
  • Determine the incidence of relapse, disease-free survival, and overall survival of patients treated with this regimen.
  • Determine the survival rate at 100 days post-transplantation in patients treated with this regimen.
  • Determine the incidence of regimen-related complications (infection, hepatic veno-occlusive disease, and interstitial pneumonitis) in patients treated with this regimen.
  • Determine the incidence of primary and secondary graft failure in patients treated with this regimen.
  • Determine the rates and kinetics of donor-derived lymphoid, myeloid, neutrophil, RBC, and platelet engraftment in patients treated with this regimen.

OUTLINE: Patients receive a non-myeloablative conditioning regimen comprising fludarabine IV over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1. Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.

Patients undergo multiple unit umbilical cord blood transplantation on days 0-1. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.

Patients are followed monthly for 6 months; at 9, 12, 14, 16, 18, and 24 months; and then annually thereafter.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 2 years.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • One of the following histologically confirmed diagnoses:

    • Acquired severe aplastic anemia

      • Meets at least 2 of the following criteria:

        • Granulocyte count less than 500/mm^3
        • Platelet count less than 20,000/mm^3
        • Absolute reticulocyte count less than 20,000/mm^3 (after correction for hematocrit)
      • Unresponsive to OR recurrent disease after prior treatment with anti-thymocyte globulin and/or cyclosporine
    • Acute myeloid leukemia (AML), meeting 1 of the following criteria:

      • Failed induction therapy
      • In first complete remission (CR) with any of the following high-risk features:

        • Stem cell or biphenotype classification (M0)
        • Erythroleukemia (M6)
        • Acute megakaryocytic leukemia (M7)
        • Cytogenetic markers indicative of poor prognosis
        • t(15;17) translocation and failed first-line induction therapy OR there is molecular evidence of persistent disease
        • t(8;21) and inv(16) translocations and failed first-line induction therapy
      • In early relapse*
      • In second or subsequent remission
      • Recurrent disease after prior autologous stem cell transplantation (SCT) NOTE: *No refractory relapse
    • Acute lymphoblastic leukemia, meeting 1 of the following criteria:

      • In early relapse*
      • In second or subsequent remission
      • In first CR with the following high-risk features:

        • t(4;11) or t(9;22) translocation
        • Hyperleukocytosis (initial WBC greater than 30,000/mm^3)
        • Failed to achieve CR by day 28 of standard induction therapy
      • Recurrent disease after prior autologous SCT NOTE: *No refractory relapse
    • Chronic myelogenous leukemia

      • Chronic or accelerated phase that has failed medical management
      • Blastic phase allowed after reinduction chemotherapy induces chronic phase
    • Myelodysplastic syndromes meeting 1 of the following criteria:

      • Refractory to medical management
      • Presence of cytogenetic abnormalities predictive of transformation to acute leukemia, including the following:

= 5q- = 7q-

  • Monosomy 7 and trisomy 8
  • Evidence of evolution to AML (e.g., refractory anemia with excess blasts [RAEB], or RAEB in transformation)

    • Chronic lymphocytic leukemia

      • Refractory to treatment including fludarabine-based therapy
      • Recurrent disease after prior autologous SCT
    • Multiple myeloma

      • Recurrent disease after prior autologous SCT
      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
    • Hodgkin's lymphoma

      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
    • Non-Hodgkin's lymphoma (NHL)

      • Recurrent disease after prior autologous SCT
      • Beyond first CR or failed induction therapy
      • Disease is sensitive to pretransplantation cytoreduction
      • Mantle zone NHL allowed after induction therapy
    • Myeloproliferative disorders

      • Refractory to medical management
      • Allografting required unless grade 3 or greater myelofibrosis by bone marrow biopsy

        • No HLA-matched sibling donor available
        • Ineligible for a myeloablative conditioning regimen due to advanced age (over 55), extensive prior therapy, and/or other comorbidities
        • If under age 55, must meet at least 1 of the following criteria:
    • Received extensive prior therapy
    • Organ toxicity or infection precluding eligibility for allogeneic transplantation with full ablation conditioning

      • Availability of 2-5 umbilical cord blood units that are at least a 4/6 HLA match
      • No active CNS disease
      • No primary or grade 3 or 4 myelofibrosis

PATIENT CHARACTERISTICS:

Age

  • Any age

Performance status

  • Karnofsky 70-100% (for patients 16 years of age and older)
  • Lansky 50-100% (for patients under 16 years of age)

Life expectancy

  • At least 3 months

Hematopoietic

  • See Disease Characteristics

Hepatic

  • ALT/AST less than 4 times normal
  • Bilirubin less than 2.0 mg/dL (unless due to hepatic infiltration by primary malignancy)

Renal

  • Creatinine clearance greater than 40 mL/min

Cardiovascular

  • Shortening fraction or ejection fraction greater than 40% of normal value for age by echocardiogram or radionuclide scan

Pulmonary

  • FVC and FEV_1 greater than 60% of predicted
  • DLCO greater than 60% of predicted (adult patients)
  • Clearance by pulmonologist required if patient cannot perform pulmonary function tests

Other

  • Not pregnant or nursing
  • No uncontrolled active infection (viral, bacterial, or fungal)
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • More than 3 months since prior autologous stem cell transplantation

Chemotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • Recovered from prior therapy
  • No other concurrent investigational agents that would preclude study participation or increase risk to patient

    • Investigational diagnostic procedures allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00054236

Locations
United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Principal Investigator: Brenda Cooper, MD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00054236     History of Changes
Other Study ID Numbers: CWRU6Y01, P30CA043703, CWRU6Y01, 12-01-32J
Study First Received: February 5, 2003
Last Updated: September 11, 2012
Health Authority: United States: Federal Government

Keywords provided by Case Comprehensive Cancer Center:
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
adult acute myeloid leukemia in remission
childhood acute myeloid leukemia in remission
recurrent adult acute myeloid leukemia
recurrent childhood acute myeloid leukemia
adult erythroleukemia (M6a)
childhood acute erythroleukemia (M6)
adult acute minimally differentiated myeloid leukemia (M0)
childhood acute minimally differentiated myeloid leukemia (M0)
adult acute megakaryoblastic leukemia (M7)
childhood acute megakaryocytic leukemia (M7)
adult acute lymphoblastic leukemia in remission
childhood acute lymphoblastic leukemia in remission
recurrent adult acute lymphoblastic leukemia
recurrent childhood acute lymphoblastic leukemia
accelerated phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
previously treated myelodysplastic syndromes
refractory chronic lymphocytic leukemia
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
recurrent/refractory childhood Hodgkin lymphoma
polycythemia vera
primary myelofibrosis
essential thrombocythemia
refractory multiple myeloma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma

Additional relevant MeSH terms:
Anemia
Anemia, Aplastic
Neoplasms
Leukemia
Lymphoma
Multiple Myeloma
Neoplasms, Plasma Cell
Plasmacytoma
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Lymphoma, Large-Cell, Immunoblastic
Myelodysplastic-Myeloproliferative Diseases
Hematologic Diseases
Bone Marrow Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hemorrhagic Disorders
Precancerous Conditions
Lymphoma, Non-Hodgkin
Antilymphocyte Serum
Cyclophosphamide

ClinicalTrials.gov processed this record on July 20, 2014